Core Insights - Jiangsu Hengrui Medicine Co., Ltd. reported a revenue of 15.761 billion yuan for the first half of 2025, marking a year-on-year increase of 15.88% [1] - The net profit attributable to shareholders reached 4.45 billion yuan, reflecting a growth of 29.67% year-on-year [1] - Operating cash flow net amount was 4.3 billion yuan, up by 41.80% compared to the previous year [1] Revenue Breakdown - The sales and licensing income from innovative drugs amounted to 9.561 billion yuan, accounting for 60.66% of total revenue, with innovative drug sales alone contributing 7.570 billion yuan [1] - The company received upfront payments of 200 million USD from Merck and 75 million USD from IDEAYA for licensing agreements, which further boosted revenue [1] R&D Investment - Hengrui Medicine invested 3.871 billion yuan in R&D during the reporting period, with 3.228 billion yuan classified as expense-based R&D [2] - Cumulative R&D investment exceeded 48 billion yuan, supporting a surge in innovative outcomes [1][2] Product Approvals and Pipeline - Six Class 1 innovative drugs were approved for market launch, including injection of Ricacizumab and others [2] - The company has over 100 self-developed innovative products in clinical development and more than 400 clinical trials ongoing domestically and internationally [2] Strategic Collaborations - Hengrui Medicine has strengthened international cooperation, granting exclusive global rights for the oral small molecule drug HRS-5346 to Merck outside Greater China [2] - The company also entered into a collaboration agreement with GSK to co-develop up to 12 innovative drugs across various therapeutic areas [2] Employee Incentives - To enhance team cohesion and core competitiveness, Hengrui Medicine announced a share buyback plan of 1 to 2 billion yuan for a new employee stock ownership plan, with an incentive scale not exceeding 14 million shares in 2025 [3]

盘前投资策略 四川大决策投顾 核心观点： 指数短期或延续震荡格局 情绪强分歧或是低吸良机 2025-08-20 行情回顾 国际方面：美股周二三大指数收盘涨跌不一，纳指跌1.46%，标普500指数跌0.59%，道指涨0.02%。热 门中概股普跌，纳斯达克中国金龙指数收跌0.9%。 A股方面：周二沪深创三大股指全天宽幅震荡，收盘均微跌，日K线报收十字星。盘面出现分歧，个股 涨多跌少，涨跌比为2984：2255。板块方面，动物保健、钨、白酒、机器人、减速器等涨幅居前，保 险、兵装重组概念、地面兵装、钴、玻璃玻纤、半导体材料、航空装备等跌幅居前。沪深两市全天成交 额2.59万亿，较上个交易日缩量1758亿，成交额连续5个交易日超2万亿。 周二市场资金主要流向白酒板块，驱动因素是：消息面上，据报道，高层强调，要进一步提升宏观政策 实施效能，深入评估政策实施情况，及时回应市场关切，稳定市场预期。要抓住关键着力点做强国内大 循环。持续激发消费潜力，系统清理消费领域限制性措施，加快培育壮大服务消费、新型消费等新增长 点。 主力动向 1、大盘成交量 周二上证指数单边成交10609亿元，深成指单边成交15275亿元，沪深两市全天 ...

Core Insights - The company reported a revenue of approximately RMB 15.761 billion for the first half of 2025, representing a year-on-year growth of 15.9% [1] - Net profit attributable to shareholders was RMB 4.45 billion, reflecting a year-on-year increase of 29.7% [1] - Basic earnings per share were RMB 0.70 [1] Revenue Breakdown - The growth in revenue and profit was primarily driven by increased sales and licensing income from innovative drugs, which amounted to RMB 9.561 billion, a year-on-year increase of 26.8%, accounting for 60.7% of total revenue [1] - Sales revenue from innovative drugs reached RMB 7.57 billion [1] Innovative Drug Performance - Key innovative drugs such as Rivoceranib, Darsylin, and Henggrelizumab have effectively addressed unmet clinical needs, with strong clinical data gaining recognition from doctors and patients, leading to continued rapid revenue growth [1] - Earlier launched innovative drugs like Arixtra, Remimazolam, Pyrotinib, and Fluorouracil have expanded their application scope due to accumulating post-market research evidence and new indications, contributing to sales revenue [1] - Other innovative products like Apatinib, Sulfapyridine, and Hecuqipob have also seen growth during the reporting period [1] Licensing Income - The company recognized licensing income as a regular business activity, with significant payments received from Merck Sharp & Dohme (USD 200 million) and IDEAYA Biosciences (USD 75 million), further boosting operational performance [2] Generic Drug Performance - Although sales revenue from generic drugs included in centralized procurement experienced a slight decline, high-quality generic products such as Liposomal Bupivacaine and the first approved generic product of Albumin-bound Paclitaxel in the U.S. saw rapid revenue growth, leading to a slight overall increase in generic drug business revenue [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年8月20日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 江苏恒瑞医药股份有限公司 2025 年半年度报告 公司代码：600276 ...

智通财经APP获悉，8月20日，恒瑞医药(股票代码：600276.SH；01276.HK)发布2025年半年度报告。报 告显示，2025年上半年，公司实现营业收入157.61亿元，同比增长15.88%；归属于上市公司股东的净利 润44.50亿元，同比增长29.67%；经营性现金流净额达43.00亿元，同比增长41.80%。营收、净利及经营 性现金流净额均创往年同期新高，业绩进入爆发增长期。公司持续加大创新力度，维持较高的研发投 入，报告期内公司研发投入38.71亿元，其中费用化研发投入32.28亿元。 为了增强团队凝聚力及公司核心竞争力，充分发挥长效激励机制，恒瑞医药还同时公告将回购10-20亿 元的股份，用于实行新的员工持股计划，2025年激励规模不超过1400万股。 创新药销售引领业绩增长，对外许可成常态化业务 从业绩角度来看，持续的高强度研发投入加快公司转型升级步伐，公司迈入了创新药丰收期，创新药收 入持续提升。2025年上半年公司创新药销售及许可收入95.61亿元，占公司营业收入比重60.66%，其中 创新药销售收入75.70亿元。瑞维鲁胺、达尔西利、恒格列净等医保内创新药优异的临床数据在实践中 得到 ...

8月20日，恒瑞医药（股票代码：600276.SH；01276.HK）发布2025年半年度报告。报告显示，2025年 上半年，公司实现营业收入157.61亿元，同比增长15.88%；归属于上市公司股东的净利润44.50亿元， 同比增长29.67%；经营性现金流净额达43.00亿元，同比增长41.80%。营收、净利及经营性现金流净额 均创往年同期新高，业绩进入爆发增长期。公司持续加大创新力度，维持较高的研发投入，报告期内公 司研发投入38.71亿元，其中费用化研发投入32.28亿元。 为了增强团队凝聚力及公司核心竞争力，充分发挥长效激励机制，恒瑞医药还同时公告将回购10-20亿 元的股份，用于实行新的员工持股计划，2025年激励规模不超过1400万股。 创新药销售引领业绩增长，对外许可成常态化业务 从业绩角度来看，持续的高强度研发投入加快公司转型升级步伐，公司迈入了创新药丰收期，创新药收 入持续提升。2025年上半年公司创新药销售及许可收入95.61亿元，占公司营业收入比重60.66%，其中 创新药销售收入75.70亿元。瑞维鲁胺、达尔西利、恒格列净等医保内创新药优异的临床数据在实践中 得到广泛验证，临床价值获 ...

Group 1 - The World Lung Cancer Conference (WCLC) is set to showcase numerous innovative drugs from Chinese pharmaceutical companies, highlighting the potential investment opportunities in the sector [1] - Several leading innovative drug companies will present significant new products during the WCLC, including key studies on anti-PD-1 monoclonal antibodies and other targeted therapies [1] - The Chinese innovative drug industry is entering a new phase of high-quality development, characterized by rapid advancements in research and development [3] Group 2 - Over 1,250 innovative drugs are currently in the research phase in China, a number that has nearly increased tenfold compared to a decade ago, indicating significant growth in the sector [3] - The total amount of innovative drug transactions abroad reached nearly $50 billion in the first half of 2025, with upfront payments exceeding $2 billion, suggesting a record-breaking year ahead [3] - More than 100 innovative drugs have been included in the preliminary list for commercial insurance coverage, signaling a potential second growth curve for the innovative drug market [5] Group 3 - The innovative drug industry is transitioning from policy-driven growth to value realization, with companies that possess global competitiveness expected to thrive through differentiated innovation and international expansion [7] - Investors are encouraged to track policy implementation, clinical trial progress, and overseas commercialization to seize medium to long-term structural opportunities in the innovative drug sector [7] - The innovative drug ETFs and related funds are recommended as effective tools for investors looking to gain exposure to the innovative drug industry [7]

隔夜，全球AI总龙头英伟达收盘下跌3.5%，软件公司Palantir和芯片设计公司Arm分别重挫9.4%和5%。 科技板块的下跌，带动纳指下跌了1.4%。 美股科技板块下跌的原因在于，麻省理工学院发布了一篇题为《生成式AI鸿沟：2025年商业AI现状》 的报告。 该报告指出，高达95%的企业从其生成式AI投资中获得的回报为零。OpenAI首席执行官Sam Altman近 期也敲响了AI投资警钟，他认为AI相关股票已出现泡沫迹象。两个消息共同刺激了投资者对美股科技 板块的谨慎态度。 尽管如此，也有不少对AI热潮持正面看法的观点出现。 即便是敲响AI投资警钟的Sam Altman，其动作却很诚实。Sam Altman准备让OpenAI投入数万亿美元建 设数据中心，还多方寻求算力合作。 对于AI是否有泡沫，达哥认为，真正的投资高手不是回避泡沫，而是看清它、利用它，并在大众狂欢 结束前悄然离场。 昨天，有一篇文章在投资圈流传。文章的主要意思是，在牛市中，下车了真正有价值的标的，就会很难 再上车，因为下车之后过一段时间会发现，卖出的个股继续上涨。 此时内心在想：便宜的时候我都卖了，现在再去买就下不了手。在错过有真正价值 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 42.53, up from a previous target of HKD 28.95 [7]. Core Insights - The company reported a revenue of HKD 74.34 billion for H1 2025, representing a year-on-year increase of 14%, with net profit rising by 15% to HKD 31.35 billion. The revenue from innovative drugs reached HKD 61.45 billion, up 22% year-on-year, accounting for 83% of total revenue [1]. - The company is expected to achieve a sales revenue of over HKD 100 billion from innovative drugs by 2025, with a revenue share exceeding 80% [3]. - The company has a robust pipeline with over 40 new molecular entities under research and has consistently achieved high-quality external licensing agreements, totaling USD 7.3 billion over the past three years [3]. Revenue Breakdown by Therapeutic Areas - Oncology: Revenue of HKD 45.31 billion (+1% year-on-year), driven by Amivantamab and other milestone payments, with product sales growth exceeding 20% after excluding collaboration revenue [2]. - Anti-infectives: Revenue of HKD 7.35 billion (+5% year-on-year), primarily driven by Adefovir [2]. - CNS: Revenue of HKD 7.68 billion (+5% year-on-year), mainly driven by Inalizumab [2]. - Metabolic and other diseases: Revenue of HKD 14.00 billion (+142% year-on-year), driven by milestone payments for GLP-1 and HS-20094 [2]. Pipeline and Clinical Development Updates - The company is advancing its pipeline with several drugs in various stages of clinical trials, including HS-20093 and HS-20089, which are expected to enter critical clinical phases in the coming years [4]. - The company is actively expanding into skin and kidney autoimmune diseases, with several candidates already in Phase III clinical trials [4]. Profit Forecast and Valuation - The forecasted net profit for 2025-2027 is HKD 52.02 billion, HKD 54.80 billion, and HKD 57.27 billion, respectively, with corresponding EPS of HKD 0.88, HKD 0.92, and HKD 0.96 [5]. - The company’s SOTP valuation is estimated at HKD 2529.44 billion, with innovative drugs valued at HKD 2483.38 billion and generics at HKD 46.06 billion [5][12].

Group 1 - QFII has accelerated its investment in the Chinese capital market, with total holdings in disclosed A-share companies exceeding 20.4 billion yuan as of the end of Q2 2025, reflecting foreign investors' long-term confidence in Chinese assets [1][2] - The investment structure of QFII is broad and deep, covering key sectors such as non-ferrous metals, non-bank financials, pharmaceuticals, and hardware equipment, with a particular focus on technology and manufacturing [2][3] - The top holdings of QFII include Shengyi Technology with a holding value of 9.55 billion yuan, followed by Ninebot and Oriental Yuhong with 1.169 billion yuan and 1.017 billion yuan respectively, indicating strong recognition of their fundamentals by foreign investors [2] Group 2 - QFII has actively adjusted its portfolio in Q2, significantly increasing holdings in 30 stocks, mainly in the non-ferrous metals and hardware equipment sectors, with Alloy Investment and New Power Financial being notable examples of substantial increases [3] - Among the 117 heavily held stocks, 56 were newly added by QFII in Q2, indicating a strong willingness to seek new investment targets [3] - Major global investment institutions, including Abu Dhabi Investment Authority and Morgan Stanley, are collectively optimistic about A-shares, with the former holding nearly 2.9 billion yuan in 9 stocks by the end of Q2 [5]